Need Help?
Contact Us

Caution: Eluvia is an investigational device. Limited by US law to investigational use only. Not available for sale.

Clinical History of Restenosis1


Restenosis in the SFA


Due to the biological environment and significant mechanical forces in the SFA, the timing of restenosis is longer than in other anatomies. As a result, engineers for the Eluvia Drug-Eluting Stent needed to identify the right formulation of paclitaxel and polymer to tune an elution curve that would help ensure the drug is available when restenosis is most likely to occur.

 

Clinical History of Restenosis1


“The Eluvia stent is unique in the way in which the polymer is essentially designed and fine-tuned to produce a sustainable release of paclitaxel over time.”

Juan Granada, MD
President and CEO, Cardiovascular Research Foundation
New York, NY

 

Drug Tissue Concentrations Over Time2


Sustained Drug Release Beyond 12 Months


The Eluvia Drug-Eluting Stent is the first stent for the SFA designed to match the release of paclitaxel to the restenotic cascade for better healing and patency. The stent leverages SUSTEND™ drug-delivery technology, a polymer-based technology with proven biocompatibility that has been implanted in more than 10 million patients. 

 

Drug Tissue Concentrations Over Time2


Designed for Better Patient Outcomes

See how the Eluvia Drug-Eluting Stent leverages proven Boston Scientific technologies to lead the way in the emerging world of drug-eluting therapies for the SFA and help improve patients’ lives.

Stent Design & Delivery


Built on the foundation of the next-generation Innova™ Stent platform, the Eluvia Drug-Eluting Stent is designed to provide uniform scaffolding for drug delivery while optimizing flexibility, radial strength and fracture resistance.

Stay Up to Date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

Explore DE Resources

Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.

Top